Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities

Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario

BMO Capital analyst Do Kim raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $134.00 (from $99.00) while maintaining an Outperform rating following strong APOLLO data.

"We believe an early restart of Fitusiran trials and positive Givosiran interim data (mid-2018) would enable shares to approach our $165 upside scenario," the analyst said.

Alnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan Stanley

Morgan Stanley raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $101.00 (from $50.00) while maintaining a Equalweight rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $135 at Bernstein

Bernstein raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $135.00 (from $94.00) while maintaining a Outperform rating.

Analyst Vincent Chen echos his previous LT optimism in the company and expects siRNA to evolve into a new class of drugs which... More

UPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann

(Updated - September 21, 2017 7:08 AM EDT)

(updated to add analyst comment)

Ladenburg Thalmann analyst Christopher James raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $146.00 (from $90.00) while maintaining a Buy rating.

The analyst is positive on the results from... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse

Credit Suisse analyst Alethia Young raised her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $96.00) while maintaining an Outperform rating following positive APOLLO trial data.

Young thinks porphyria data in mid-2018 and patisiran's expansion into the cardiac subtype can continue... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company

Needham & Company analyst Alan Carr raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $85.00) while maintaining a Buy rating after the company announced positive top-line results from Phase 3 APOLLO trial in TTR Amyloidosis.

"Notably, primary mNIS+7 and key secondary Norfolk QOL-DN endpoint... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel

Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $83.00 (from $56.00) while maintaining a Hold rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'

Cowen raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $117.00 (from $93.00) while maintaining a Outperform rating after the company released positive top-line data from the pivotal Ph3 APOLLO trial of patisiran in FAP with strong statistical significance.

Analyst Ritu Baral... More

Arbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP-Enabled Patisiran Program

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced today that the Company's lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. Patisiran is enabled by Arbutus lipid nanoparticle (LNP) technology. The program represents the most clinically advanced application of Arbutus proprietary LNP delivery... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper Jaffray

(updated to expand analyst comment)

Piper Jaffray analyst Edward Tenthoff raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $110.00) while maintaining a Overweight rating following positive APOLLO Phase 3 data on patisiran.

The analyst anticipates cardiac subgroup data with the... More

Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%

Alnylam Pharma (NASDAQ: ALNY) pushes to highs following earlier positive data. Shares are now p 39.6%.

Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints

Sanofi Genzyme and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met... More

Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints

Sanofi Genzyme, the specialty care global business unit of Sanofi (NYSE: SNY), and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met... More